CYP2D6 Genotype and Phenotype in Amerindians of Tepehuano Origin and Mestizos of Durango, Mexico

  title={CYP2D6 Genotype and Phenotype in Amerindians of Tepehuano Origin and Mestizos of Durango, Mexico},
  author={Martha Sosa-Mac{\'i}as and Guillermo Elizondo and Carmen Flores-P{\'e}rez and Janett Flores-P{\'e}rez and Francisco Bradley-Alvarez and Ruth Elizabeth Alan{\'i}s-Ba{\~n}uelos and Ismael Lares-Asseff},
  journal={The Journal of Clinical Pharmacology},
Although the drug‐metabolizing enzyme CYP2D6 has been studied extensively in subjects of differing ethnicities, limited CYP2D6 pharmacogenetic data are available for the Amerindian population and Mestizos of Mexico. Dextromethorphan hydroxylation phenotype was studied in Tepehuano Amerindian (n = 58) and Mestizo (n = 88) subjects, and 195 individuals (85 Tepehuano Amerindians and 110 Mestizos) were genotyped by polymerase chain reaction‐restriction fragment length polymorphism methods to… 

A Comparative Study of CYP3A4 Polymorphisms in Mexican Amerindian and Mestizo Populations

The frequencies of the CYP3A4*1B variant in Mestizos and Tepehuanos were similar to those reported for Caucasians, but different from those observed for African and Asian populations.

Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.

In general, the wild-type allele (*1) of both genes was predominant in Mexican populations, outlining a relatively homogeneous distribution for CYP2C19 and CyP2D6.

CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.

The data show a lower frequency of CYP2D6 inactive alleles and a higher frequency of duplication/multiplication of CYp2D 6 active alleles in indigenous populations that in Mestizos.

CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards

The present data suggest the need for pharmacogenetic studies to optimize drug dosages in different populations, and add further evidence about CYP2C9 genetic diversity within Hispanic populations with regard to their ancestry.

Influence of CYP2D6 Deletion, Multiplication, –1584C→G, 31G→A and 2988G→A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos

The polymorphisms studied had different frequencies between Tepehuanos and Mestizos (p < 0.001); however, in the Tepehuano group these had a low influence on their phenotypic expression, which helps to understand the genotype-phenotype relationships of CYP2D6 in the studied populations.

Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations

The frequencies of the CYP2D6*3 and CYP6*4 alleles are low for the Peruvian mestizo population compared to the Latin American and tricontinental population, due to their natural population evolution, which is manifested by their decreased metabolic activity.

CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: Pharmacogenetics and anthropological implications

The results are consistent with the known genetic admixture origin of most Venezuela populations and highlight the need for pharmacogenetic studies taking into account biogeographical and anthropological considerations.

Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos.

This study is the first comprehensive resequencing analysis of CYP2D6 in Mexicans or any other Latin American population, providing information about genetic diversity relevant in the development of pharmacogenomics in this region.

CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas.

The present data support previous findings reporting a very low frequency of CYP2D6 PMs in Mexican-Amerindians and the predicted UM phenotype in both MMs and MLs was lower than those reported for most Mexican populations.

Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes

It is shown that extrapolation from other populations is not appropriate for pharmacogenomic research in AI/AN populations and the combination of nonfunctional CYP2D6*3 and putative reduced function CYP3A4*1G alleles may predict diminished clearance of CYp3A substrates.



Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile.

The major differences between Mapuches and Asians were for CYP2D6*10 and CYP1A1 allelic frequencies, as well as the absence of the common Chinese 44 kb XbaI fragment of CYP3D6, the highest frequency reported to date.

Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.

The present pilot study revealed major similarities in the polymorphic CYP2D locus between Korean, Japanese and Chinese populations.

Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.

The over-all RFLP and PCR analyses point to a diminished genetic diversity for the Ngawbe subjects, consistent with their demographic history and population genetics.

Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations.

It is proposed that in earlier hominids and humans, CYP2D6 had increasingly become a vestigial characteristic unconstrained by dietary stressors, as a result of cultural survival strategies.

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

A solid basis is provided for prediction of CYP2D6 capacity, as required in drug research and routine drug treatment, and significant differences in enzymatic activity measured by the dextromethorphan metabolic ratio (MR) are shown.

Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.

The results indicate the common existence in Tanzanians of a variant CYP2D6 form with different substrate specificity as compared to the wild-type form of the enzyme causing reduced capacity for debrisoquine metabolism.

Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.

The results confirm the large ethnic differences in probe drug metabolism and quinidine sensitivity among these ethnic groups and suggest that the Ghanaians have an additional unidentified allele(s) with altered substrate specificity and qu inidine sensitivity which is currently genotyped as CYP2D6*1.

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.

This study demonstrates the efficiency of the PCR-test for phenotype prediction; 96.4% of individuals were correctly predicted, i.e., 100% of the extensive metabolizers (EMs) and 86.0%" of the poor metabolizer phenotype (PMs).

Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6

The C/T188,G/A1934, G/C4268, and RFLP polymorphisms may explain the interracial variations between Chinese and white subjects, as well as the genetic variations among Chinese subjects.

Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

Important interethnic differences exist in the structure of the CYP2D locus, and they suggest that the frequent distribution of the C188-->T mutation among the CYp2D6Ch genes explains the lower capacity among Chinese to metabolize drugs that are substrates of CYP 2D6, such as antidepressants and neuroleptic agents.